The present invention relates to a novel spiroquinone derivative compound, a production method thereof, and a pharmaceutical composition for preventing or treating neurological disorders which contains the compound as an active ingredient

A first tire member manufacturing method includes an operation in which a master batch is made, and an operation in which the master batch, peptizing agent, and processing additive are mixed. The operation in which the master batch is made includes an operation in which carbon-black-containing pre-coagulation rubber latex is coagulated to obtain a coagulum, an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum, and an operation in which the compound according to Formula (I) is dispersed within the coagulum.

##STR00001##

In Formula (I), R.sup.1 and R.sup.2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons. R.sup.1 and R.sup.2 may be the same or different. M.sup.+ indicates sodium ion, potassium ion, or lithium ion.

A first tire member manufacturing method includes an operation in which a master batch is made, and an operation in which the master batch, peptizing agent, and processing additive are mixed. The operation in which the master batch is made includes an operation in which carbon-black-containing pre-coagulation rubber latex is coagulated to obtain a coagulum, an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum, and an operation in which the compound according to Formula (I) is dispersed within the coagulum.

##STR00001##

In Formula (I), R.sup.1 and R.sup.2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons. R.sup.1 and R.sup.2 may be the same or different. M.sup.+ indicates sodium ion, potassium ion, or lithium ion.

The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

The invention relates to new -vinyl carbonylated compounds corresponding to general formula (I), wherein R.sub.1, R.sub.2,R.sub.3, R.sub.4, R.sub.5 and Y are as defined in claim 1, their isomers, their diastereoisomers and acid addition salts or a pharmaceutically acceptable base. The invention also relates to a method for producing said compounds (I). It further relates to the use of said compound (I) as selective metalloprotease inhibitors, especially matrix metalloproteases 12 (MMP-12) and/or 9 (MMP-9). The compounds (I) are particularly useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD), particularly emphysema induced by cigarette smoke. ##STR00001##

The invention relates to new -vinyl carbonylated compounds corresponding to general formula (I), wherein R.sub.1, R.sub.2,R.sub.3, R.sub.4, R.sub.5 and Y are as defined in claim 1, their isomers, their diastereoisomers and acid addition salts or a pharmaceutically acceptable base. The invention also relates to a method for producing said compounds (I). It further relates to the use of said compound (I) as selective metalloprotease inhibitors, especially matrix metalloproteases 12 (MMP-12) and/or 9 (MMP-9). The compounds (I) are particularly useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD), particularly emphysema induced by cigarette smoke. ##STR00001##

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compounds and compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.